We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Purple Biotech Ltd (PPBT) ADR Each Representing 200 Ord Shares SPON

Sell:$3.33 Buy:$3.48 Change: $0.03 (0.87%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$3.33
Buy:$3.48
Change: $0.03 (0.87%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Sell:$3.33
Buy:$3.48
Change: $0.03 (0.87%)
Market closed |  Prices as at close on 20 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

Contact details

Address:
4 Oppenheimer St., Science Park
REHOVOT
7670104
Israel
Telephone:
+972 (3) 9333121
Website:
https://purple-biotech.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PPBT
ISIN:
US74638P2083
Market cap:
$9.91 million
Shares in issue:
15.76 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Eric Rowinsky
    Chairman of the Board
  • Itzhak Israel
    Chief Executive Officer & Director
  • Gil Efron
    Deputy Chief Executive Officer, Chief Financial Officer
  • Gil Ben-Menachem
    Vice President - Business Development
  • Avraham Ben-Tzvi
    General Counsel, Secretary
  • Yisrael Gewirtz
    Internal Auditor
  • Bertrand Liang
    Chief Medical Officer
  • Hadas Reuveni
    Founder and Chief Technology Officer of TyrNovo (a subsidiary)
  • Michael Schickler
    Head of Clinical Operations

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.